Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/64331
Type
ArticleCopyright
Restricted access
Embargo date
3100-12-31
Collections
Metadata
Show full item record
BREAKTHROUGH MPOX OUTBREAK INVESTIGATION, THE DELICATE BALANCE BETWEEN HOST IMMUNE RESPONSE AND VIRAL IMMUNE ESCAPE
Author
Affilliation
Department of Internal Medicine and Infectious Diseases. Vrije Universiteit Brussel. Universitair ziekenhuis Brussel. Brussels, Belgium
Department of Internal Medicine and Infectious Diseases. Vrije Universiteit Brussel. Universitair ziekenhuis Brussel. Brussels, Belgium
Clinical Virology Unit, department of clinical sciences. Institute of Tropical Medicine. Antwerp, Belgium/Research Group on Biotechnology Applied to Pathogens. René Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Bundeswehr Institute of Microbiology. Munich, Germany
Department of Internal Medicine and Infectious Diseases. Vrije Universiteit Brussel. Universitair ziekenhuis Brussel. Brussels, Belgium
Clinical Virology Unit, department of clinical sciences. Institute of Tropical Medicine. Antwerp, Belgium
Clinical Virology Unit, department of clinical sciences. Institute of Tropical Medicine. Antwerp, Belgium
Departement of Microbiology and Infection Control. Vrije Universiteit Brussel. Universitair ziekenhuis Brussel. Brussels, Belgium/AIMS lab. Center for Neurosciences. Faculty of Medicine and Pharmacy. Vrije Universiteit Brussel. Brussels, Belgium
Department of Internal Medicine and Infectious Diseases. Vrije Universiteit Brussel. Universitair ziekenhuis Brussel. Brussels, Belgium
Department of Internal Medicine and Infectious Diseases. Vrije Universiteit Brussel. Universitair ziekenhuis Brussel. Brussels, Belgium
Clinical Virology Unit, department of clinical sciences. Institute of Tropical Medicine. Antwerp, Belgium/Research Group on Biotechnology Applied to Pathogens. René Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Bundeswehr Institute of Microbiology. Munich, Germany
Department of Internal Medicine and Infectious Diseases. Vrije Universiteit Brussel. Universitair ziekenhuis Brussel. Brussels, Belgium
Clinical Virology Unit, department of clinical sciences. Institute of Tropical Medicine. Antwerp, Belgium
Clinical Virology Unit, department of clinical sciences. Institute of Tropical Medicine. Antwerp, Belgium
Departement of Microbiology and Infection Control. Vrije Universiteit Brussel. Universitair ziekenhuis Brussel. Brussels, Belgium/AIMS lab. Center for Neurosciences. Faculty of Medicine and Pharmacy. Vrije Universiteit Brussel. Brussels, Belgium
Department of Internal Medicine and Infectious Diseases. Vrije Universiteit Brussel. Universitair ziekenhuis Brussel. Brussels, Belgium
Abstract
Background: Limited data is available on Mpox breakthrough infections.
Purpose: Investigate a Mpox breakthrough outbreak in three vaccinated individuals.
Methods: Study participants provided informed consent. Serology testing was performed in one involved individual (ID-1) using an in-house assay detecting anti-orthopoxvirus IgG. Whole genome sequencing (WGS) was carried out and compared to the reference sequence ON563414.3 (https://www.ncbi.nlm.nih.gov/nuccore/ON563414.3/).
Results: Three individuals vaccinated with modified vaccinia Ankara–Bavaria Nordic contracted Mpox following one sexual intercourse event. One of them (ID-1) had received only one vaccine dose, while the other two were fully vaccinated. ID-1 presented to the sexual health clinic of the Universitair Ziekenhuis Brussel with proctitis related to Mpox. Despite one vaccination, serology testing Three months post vaccine showed absence of Mpox virus (MPXV) specific antibodies in ID-1. In contrast, two weeks following the sexual intercourse, seroconversion occurred. WGS of the isolated MPXV showed, compared to the reference sequence, a total of seven single nucleotide variants with four of them indicating protein amino-acid changes.
Conclusion: Incomplete MPXV vaccination as well as MPXV variants might result in breakthrough infections. Preventive measures, such as MPVX vaccination, could maintain immunity in individuals with higher risk of MPXV infection, and might lower disease severity.
Share